Article

Inhibitor of the nuclear transport protein XPO1 enhances the anticancer efficacy of KRAS G12C inhibitors in preclinical models of KRAS G12C mutant cancers

2022-01-28

Abstract excerpt

<h4>ABSTRACT</h4> The identification of molecules that can bind covalently to KRAS G12C and lock it in an inactive GDP-bound conformation has opened the door to targeting KRAS G12C selectively. These agents have shown promise in preclinical tumor models and clinical trials. FDA has recently granted approval to sotorasib for KRAS G12C mutated non-small cell lung cancer (NSCLC). However, patients receiving these ag...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 26afae36-368e-5c5d-b2b9-753421891cff
DOI: 10.1101/2022.01.26.477874

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Inhibitor of the nuclear transport protein XPO1 enhances the anticancer efficacy of KRAS G12C inhibitors in preclinical models of KRAS G12C mutant cancersDOI 10.1101/2022.01.26.477874Read

Molecular profiling of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in cellular and LSL-Kras G12D/+; Trp53 fl/+; Pdx1-Cre (KPC) pancreatic cancer modelSemantic proximity Read

Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinomaSemantic proximity Read

The past, present, and future of CRM1/XPO1 inhibitorsSemantic proximity Read

Targeting XPO1-Dependent Nuclear Export in Cancer.Semantic proximity Read

XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal CancerSemantic proximity Read

E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1Semantic proximity Read

XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.Semantic proximity Read

XPO1 inhibition modulates the Wnt/β-catenin signaling pathway to reduce colorectal cancer tumorigenesisSemantic proximity Read

Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial.Semantic proximity Read

Identification and validation of a non-genetically encoded vulnerability to XPO1 inhibition in malignant rhabdoid tumors – expanding patient-driven discovery beyond the N-of-1Semantic proximity Read

SINE (selective inhibitor of nuclear export) – translational science in a new class of anti-cancer agentsSemantic proximity Read

The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic LeukemiaSemantic proximity Read